Skip to main
AVXL
AVXL logo

AVXL Stock Forecast & Price Target

AVXL Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Anavex Life Sciences Corp has demonstrated promising advancements in its clinical pipeline, notably with ANAVEX 3-71, which has shown positive Phase 2 results for schizophrenia, suggesting a strong potential for further development in pivotal studies. The company ended fiscal 2025 with approximately $102.6 million in cash and cash equivalents, reflecting a modest increase, which supports continued investment in its therapeutics aimed at addressing significant unmet needs in central nervous system diseases. Additionally, the reduction in neuroinflammatory biomarkers indicates encouraging efficacy trends, reinforcing the company's strategic focus on precision medicine in the treatment of neurodegenerative and neurodevelopmental disorders.

Bears say

Anavex Life Sciences Corp reported a net loss of $0.54 per share, indicating ongoing financial challenges, despite a reduction in research and development expenses from $11.6 million to $7.3 million compared to the previous year. The company faces significant hurdles with its Marketing Authorisation Application for blarcamesine, receiving a negative trend vote from the European Medicines Agency's Committee for Medicinal Products for Human Use, which diminishes the likelihood of regulatory approval and market success in critical regions. Furthermore, projected net losses are anticipated to continue, with expectations of a $0.56 per share loss for fiscal 2025, compounded by various risks including potential negative clinical data and an inability to effectively launch products.

AVXL has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Anavex Life Sciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Anavex Life Sciences (AVXL) Forecast

Analysts have given AVXL a Strong Buy based on their latest research and market trends.

According to 2 analysts, AVXL has a Strong Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $22, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $22, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Anavex Life Sciences (AVXL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.